Great question! Here's a breakdown of how ALXN2220 works and what it's trying to achieve in transthyretin amyloidosis (ATTR):
What it is:
ALXN2220 is a monoclonal antibody — essentially a lab-engineered protein designed to target a very specific problem in the body.
How it works (mechanism of action)
Unlike current Show Full Answer
Great question! Here's a breakdown of how ALXN2220 works and what it's trying to achieve in transthyretin amyloidosis (ATTR):
What it is:
ALXN2220 is a monoclonal antibody — essentially a lab-engineered protein designed to target a very specific problem in the body.
How it works (mechanism of action):
Unlike current treatments that slow down amyloid buildup, ALXN2220 works as a "depleter." It recruits the immune system to actively clear amyloid deposits that have already built up in the heart. This is a meaningful distinction — it's not just stopping new damage, it's potentially reversing existing damage.
What it aims to do:
- Reduce amyloid buildup markers in the heart
- Improve heart health indicators
- Potentially reverse heart stiffness caused by amyloid deposits in ATTR with cardiomyopathy (ATTR-CM)
- Help people live longer and reduce heart-related complications
Where things stand:
Early trials showed promising results over 12 months, with no major side effects reported. It's now in Phase 3 trials. The FDA has granted it fast-track status, which speeds up the review process for serious conditions with limited options.
It's definitely one to watch — though it's worth discussing with your care team what this might mean for your specific situation.
June 10
Can I get on list for ALXN2220
June 10
Join
Your Privacy Choices
